Gut microbiota metabolites for sweetening type i diabetes

Cellular and Molecular Immunology

Volumn 15, Issue 2, 2018, Pages 92-95

  Aljutaily, Thamer ^a   Consuegra Fernández, Marta ^b   Aranda, Fernando ^b   Lozano, Francisco ^b,c,d   Huarte, Eduardo ^a  

^a SOUTH DAKOTA STATE UNIVERSITY   (United States)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID; BUTYRIC ACID; HIGH AMYLOSE RESISTANT STARCH; PROPIONIC ACID; SHORT CHAIN FATTY ACID; STARCH; UNCLASSIFIED DRUG;

ANAEROBIC BACTERIUM; ANTIGEN PRESENTING CELL; ANTIINFLAMMATORY ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BACTEROIDES; CD8+ T LYMPHOCYTE; CELL TRANSFORMATION; DIET; DRUG MECHANISM; FECAL MICROBIOTA TRANSPLANTATION; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNE SYSTEM; INSULIN DEPENDENT DIABETES MELLITUS; INTESTINE FLORA; METABOLITE; NONHUMAN; REGULATORY T LYMPHOCYTE; MICROFLORA; T LYMPHOCYTE;

DIABETES MELLITUS, TYPE 1; GASTROINTESTINAL MICROBIOME; HUMANS; MICROBIOTA; T-LYMPHOCYTES;

EID: 85041659274     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2017.65     Document Type: Article

References (15)

1. Todd JA, Bell JI, McDevitt HO. HLA-DQ beta gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature 1987; 329: 599-604.
2. Paun A, Yau C, Danska JS. The influence of the microbiome on Type 1 diabetes. J Immunol 2017; 198: 590-595.
3. Shi Y, Mu L. An expanding stage for commensal microbes in host immune regulation. Cell Mol Immunol 2017; 14: 339-348.
4. Marino E, Richards JL, McLeod KH, Stanley D, Yap YA, Knight J et al. Gut microbial metabolites limit the frequency of autoimmune T cells and protect against type 1 diabetes. Nat Immunol 2017; 18: 552-562.
5. Kolb H, von Herrath M. Immunotherapy for Type 1 diabetes: why do current protocols not halt the underlying disease process? Cell Metab 2017; 25: 233-241.
6. Turnbaugh PJ, Ridaura VK, Faith JJ, Rey FE, Knight R, Gordon JI. The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci Transl Med 2009; 1: 6ra14.
7. Anderson MS, Bluestone JA. The NOD mouse: a model of immune dysregulation. Annu Rev Immunol 2005; 23: 447-485.
8. Wen L, Ley RE, Volchkov PY, Stranges PB, Avanesyan L, Stonebraker AC et al. Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature 2008; 455: 1109-1113.
9. Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly YM et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 2013; 341: 569-573.
10. Amrani A, Verdaguer J, Serra P, Tafuro S, Tan R, Santamaria P. Progression of autoimmune diabetes driven by avidity maturation of a T-cell population. Nature 2000; 406: 739-742.
11. Marino E, Tan B, Binge L, Mackay CR, Grey ST. B-cell cross-presentation of autologous antigen precipitates diabetes. Diabetes 2012; 61: 2893-2905.
12. Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 2013; 504: 446-450.
13. Takiishi T, Cook DP, Korf H, Sebastiani G, Mancarella F, Cunha JP et al. Reversal of diabetes in NOD mice by clinical-grade proinsulin and IL-10-secreting lactococcus lactis in combination with low-dose anti-CD3 depends on the induction of Foxp3-positive T cells. Diabetes 2017; 66: 448-459.
14. Jayasinghe TN, Chiavaroli V, Holland DJ, Cutfield WS, O'Sullivan JM. The new era of treatment for obesity and metabolic disorders: evidence and expectations for gut microbiome transplantation. Front Cell Infect Microbiol 2016; 6: 15.
15. Tai N, Wong FS, Wen L. The role of gut microbiota in the development of type 1, type 2 diabetes mellitus and obesity. Rev Endocr Metab Disord 2015; 16: 55-65.